BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12153334)

  • 1. Nefazodone in the treatment of elderly patients with depressive disorders: a prospective, observational study.
    Saiz-Ruiz J; Ibañez A; Díaz-Marsá M; Arias F; Carrasco JL; Huertas D; Martín-Carrasco M; Moreno I; Rico-Villademoros F
    CNS Drugs; 2002; 16(9):635-43. PubMed ID: 12153334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression.
    Feighner J; Targum SD; Bennett ME; Roberts DL; Kensler TT; D'Amico MF; Hardy SA
    J Clin Psychiatry; 1998 May; 59(5):246-53. PubMed ID: 9632036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone.
    Elliott AJ; Russo J; Bergam K; Claypoole K; Uldall KK; Roy-Byrne PP
    J Clin Psychiatry; 1999 Apr; 60(4):226-31. PubMed ID: 10221282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of nefazodone on women with seasonal affective disorder: clinical and polysomnographic analyses.
    Shen J; Kennedy SH; Levitan RD; Kayumov L; Shapiro CM
    J Psychiatry Neurosci; 2005 Jan; 30(1):11-6. PubMed ID: 15644992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label trial of nefazodone in high comorbidity panic disorder.
    DeMartinis NA; Schweizer E; Rickels K
    J Clin Psychiatry; 1996 Jun; 57(6):245-8. PubMed ID: 8666561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which depressed patients respond to nefazodone and when?
    Trivedi MH; Rush AJ; Pan JY; Carmody TJ
    J Clin Psychiatry; 2001 Mar; 62(3):158-63. PubMed ID: 11305700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE; Franznick DA; Hollander SB; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.
    Ninan PT; Rush AJ; Crits-Christoph P; Kornstein SG; Manber R; Thase ME; Trivedi MH; Rothbaum BO; Zajecka J; Borian FE; Keller MB
    J Clin Psychiatry; 2002 May; 63(5):434-41. PubMed ID: 12025827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response.
    Perugi G; Frare F; Toni C; Ruffolo G; Torti C
    Neuropsychobiology; 2002; 46(3):145-9. PubMed ID: 12422062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nefazodone in major depression: adjunctive benzodiazepine therapy and tolerability.
    Rickels K; Schweizer E; Case WG; DeMartinis N; Greenblatt DJ; Mandos LA; Garcia España FG
    J Clin Psychopharmacol; 1998 Apr; 18(2):145-53. PubMed ID: 9580369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nefazodone in the treatment of severe, melancholic, and recurrent depression.
    Marcus RN; Mendels J
    J Clin Psychiatry; 1996; 57 Suppl 2():19-23. PubMed ID: 8626359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression.
    Cohn CK; Robinson DS; Roberts DL; Schwiderski UE; O'Brien K; Ieni JR
    J Clin Psychiatry; 1996; 57 Suppl 2():15-8. PubMed ID: 8626358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction.
    Feiger A; Kiev A; Shrivastava RK; Wisselink PG; Wilcox CS
    J Clin Psychiatry; 1996; 57 Suppl 2():53-62. PubMed ID: 8626364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
    Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
    J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind comparison of nefazodone, imipramine, and placebo in major depression.
    Fontaine R; Ontiveros A; Elie R; Kensler TT; Roberts DL; Kaplita S; Ecker JA; Faludi G
    J Clin Psychiatry; 1994 Jun; 55(6):234-41. PubMed ID: 8071277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
    Fawcett J; Marcus RN; Anton SF; O'Brien K; Schwiderski U
    J Clin Psychiatry; 1995; 56 Suppl 6():37-42. PubMed ID: 7649972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open trial of nefazodone among Hispanics with major depression: efficacy, tolerability, and adherence issues.
    Sánchez-Lacay JA; Lewis-Fernández R; Goetz D; Blanco C; Salmán E; Davies S; Liebowitz M
    Depress Anxiety; 2001; 13(3):118-24. PubMed ID: 11387731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression.
    Baldwin DS; Hawley CJ; Abed RT; Maragakis BP; Cox J; Buckingham SA; Pover GH; Ascher A
    J Clin Psychiatry; 1996; 57 Suppl 2():46-52. PubMed ID: 8626363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nefazodone for chronic daily headache prophylaxis: an open-label study.
    Saper JR; Lake AE; Tepper SJ
    Headache; 2001 May; 41(5):465-74. PubMed ID: 11380644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.